沙立度胺联合地塞米松治疗初发多发性骨髓瘤25例  

Clinical Efficacy of Thalidomide with Dexamethasone in Treatment of Twenty-five Cases Previously Untreated Multiple Myeloma

作　　者：唐雪梅[1] 何文华[1] 

机构地区：[1]四川遂宁市人民医院血液科,629000

出　　处：《肿瘤防治研究》2008年第4期282-283,共2页Cancer Research on Prevention and Treatment

基　　金：山西省科技攻关项目(2006031087-02)

摘　　要：目的观察沙立度胺联合地塞米松方案治疗多发性骨髓瘤的疗效及其不良反应。方法沙立度胺,口服,起始剂量每天50mg,50mg每晚顿服,根据患者耐受情况每周增加剂量50mg/d,直到最大剂量达到400mg/d。地塞米松40mg/d,第1～4日,第9～12日,第17～20日分别静脉或口服给药,每28日为1个疗程。该方案治疗至少3个月。结果完全缓解4例(16%),部分缓解6例(24%),进展10例(40%),无效5例(20%),总有效率80%。常见的不良反应为便秘、嗜睡、疲乏、水肿、指端麻木等。结论沙立度胺联合地塞米松是初治多发性骨髓瘤有效的治疗方案,不良反应少。Objective To study the clinical efficaey and side effects of thalidomide in combination with dexamethasone, 25 previously untreated patients with MM receiving the regimen were analyzed. Methods Thalidomide was given orally at an initial dose of 50 mg/d once per night,and then gradually increased to the maximum dose of 400 mg/d at a rate of 50 mg/d per week, according to individual tolerance. Dexamethasone was given at 40 mg/d either orally or intravenously on days 1-4,9-12 and days 17-20. Twenty-eight days a cycle, all patients were treated at least for 3 months. Results The overall efficacy of the 25 patients involved in our research is 80%, among which, 16% achieved complete remission （CR） （4cases） ,24% achieved partial remission （PR）（6eases）, and 40% had improvement, while 20% had no effect （Scases）. The mainly side effects include constipation, somnolence, edema etc. Conclusion The combination of thalidomide with dexamethasone was effective in patients with newly diagnosed myeloma, with slight side effects.

关 键 词：多发性骨髓瘤 沙立度胺 地塞米松 初治 

分 类 号：R733.3[医药卫生—肿瘤]